Symbiotic Healthcare, based in Manhattan, N.Y., has developed a capsule containing the processed fecal matter used in the C. difficile treatment fecal microbiota transplantation, according to a Crain's New York Business report.
Symbiotic Healthcare was founded by North Shore-LIJ Health System infectious disease specialist Bruce Hirsch, MD, and immunologist Gerard Honig. The company's capsule holds the processed matter and can be refrigerated for later use.
In a preliminary test including 23 patients, the pills resulted in an 87 percent cure rate.
The company is currently self-funded, but its founders are looking for financial backing, according to the report.
More Articles on C. difficile:
NIH starats clinical trial for C. diff drug
8 things to know: FMT for C. diff infection safe in immunocompromised patients
Synthetic Biologics forms clinical advisory board for C. diff prevention product